Hey SmilezSorry for the delayed response. You raise a really...

Hey Smilez

Sorry for the delayed response. You raise a really good question about aptamers, as the field is rapidly expanding and the media has claimed it as a threat to the antibody market. But if you dig a little deeper you will find that aptamers aren't anywhere near ready to rival the enormous antibody market [aptamers forecast $2.1 b market by 2018 as compared to +$100b for monoclonal antibodies]. The market surrounding monoclonal antibodies is bullish with 15% growth pa, and I find it more likely that FAB antibody fragment technology will replace a big chunk of the antibody diagnostic market. It's a good thing that BBI/Alere is pushing this forward big time as their "next generation assays". Hopefully we are involved in this.


If you want to suss out our competition, you are better off looking more into surface chemistries that are used for bioseparations and biosensors. This mini-review below gives a solid summary of conventional biosensor chemistries and an explanation as to why surface chemistries with good antibody orientation will be highly sought after leading into the future.

Antibody orientation on biosensor surfaces: a minireview